Turnstone Biologics
Driving innate and adaptive tumor immunity to provide benefit to cancer patients underserved by current treatments.
Launch date
Employees
Market cap
€13.9m
Enterprise valuation
(€41m) (Public information from Sep 2024)
Share price
$0.675 TSBX
San Francisco California (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 101m | 73.3m | 19.3m | - | - | - |
| % growth | - | (28 %) | (74 %) | - | - | - |
| EBITDA | 34.4m | (27.7m) | (56.2m) | (86.4m) | (92.8m) | - |
| % EBITDA margin | 34 % | (38 %) | (291 %) | - | - | - |
| Profit | 33.3m | (30.8m) | (55.2m) | (83.2m) | (88.7m) | (111m) |
| % profit margin | 33 % | (42 %) | (286 %) | - | - | - |
| EV / revenue | - | - | 3.0x | - | - | - |
| EV / EBITDA | - | - | -1.1x | -0.2x | -0.2x | - |
| R&D budget | 54.8m | 86.7m | 60.5m | - | - | - |
| R&D % of revenue | 54 % | 118 % | 313 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$11.3m | Series A | ||
$41.4m | Series B | ||
| N/A | N/A | - | |
| N/A | N/A | - | |
$80.0m | Series D | ||
* | N/A | $80.0m | IPO |
| Total Funding | €121m | ||
Related Content
Recent News about Turnstone Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Turnstone Biologics
Edit
ACQUISITION by Turnstone Biologics Jan 2021